Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include: Alopecia.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 1 | Alopecia |
Biomarker and diagnostic research for alopecia, androgenetic, 1 has been reported in the published literature.
8 clinical trials registered, 1 recruiting. Interventions under study include drug therapy, other interventions, and medical devices. Pipeline includes 1 PHASE4, 2 PHASE3, 1 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07056933](https://clinicaltrials.gov/study/NCT07056933) |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 3:32 AM UTC
Online Mendelian Inheritance in Man
Effect of Minoxidil Solution Iontophoresis on Androgenic Alopecia |
NA |
Cairo University |
NOT_YET_RECRUITING |
[NCT05910450](https://clinicaltrials.gov/study/NCT05910450) | A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss | PHASE3 | Cassiopea SpA | UNKNOWN |
[NCT06263413](https://clinicaltrials.gov/study/NCT06263413) | Clinical Workflow Optimization Using Artificial Intelligence for Dermatological Conditions | — | AI Labs Group S.L | UNKNOWN |
[NCT06355856](https://clinicaltrials.gov/study/NCT06355856) | Efficacy/ Safety of DNN.22.17.036 in Male Patients With Pattern Hair Loss | PHASE4 | Ache Laboratorios Farmaceuticos S.A. | UNKNOWN |
[NCT07107841](https://clinicaltrials.gov/study/NCT07107841) | Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site) | NA | Acorn Biolabs Inc. | RECRUITING |
255 publications have been identified in PubMed for alopecia, androgenetic, 1. Research spans Review / Meta-Analysis (27%), Basic Science / Preclinical (25%), and Epidemiology / Natural History (20%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 68 | 27% |
Laboratory research | 63 | 25% |
Disease patterns and progression | 50 | 20% |
Clinical study results | 45 | 18% |
New treatment approaches | 16 | 6% |
Patient case studies | 7 | 3% |
Other research | 5 | 2% |
Testing and diagnosis research | 1 | 0% |
Pindado-Ortega C (2026). [PMID: 41831780](https://pubmed.ncbi.nlm.nih.gov/41831780/). *Actas Dermosifiliogr*. [Epidemiology / Natural History]
Gupta AK (2026). [PMID: 41524216](https://pubmed.ncbi.nlm.nih.gov/41524216/). *J Dermatolog Treat*. [Epidemiology / Natural History]
Yi S (2026). [PMID: 41285252](https://pubmed.ncbi.nlm.nih.gov/41285252/). *Free radical biology & medicine*. [Gene Therapy / Novel Therapeutics]
Tang GT (2026). [PMID: 41066610](https://pubmed.ncbi.nlm.nih.gov/41066610/). *Clin Exp Dermatol*. [Epidemiology / Natural History]
Ong MM (2026). [PMID: 41118052](https://pubmed.ncbi.nlm.nih.gov/41118052/). *American journal of clinical dermatology*. [Review / Meta-Analysis]
Robbins A (2026). [PMID: 41557935](https://pubmed.ncbi.nlm.nih.gov/41557935/). *Skin Therapy Lett*. [Review / Meta-Analysis]
Altendorf S (2026). [PMID: 40638068](https://pubmed.ncbi.nlm.nih.gov/40638068/). *Physiological reviews*. [Basic Science / Preclinical]
Li G (2026). [PMID: 41748637](https://pubmed.ncbi.nlm.nih.gov/41748637/). *Nat Commun*. [Basic Science / Preclinical]
Hosny Mahmoud R (2026). [PMID: 40444884](https://pubmed.ncbi.nlm.nih.gov/40444884/). *J Investig Med*. [Gene Therapy / Novel Therapeutics]
Zhou C (2026). [PMID: 40090937](https://pubmed.ncbi.nlm.nih.gov/40090937/). *Chin Med J (Engl)*. [Clinical Trial Publication]
AI-curated news mentioning alopecia, androgenetic, 1
Updated Jul 13, 2026
Q32's recent study results for their alopecia drug demonstrate significant hair growth improvements, exceeding investor expectations. This positive outcome comes nearly two years after previous clinical setbacks impacted their stock price.
A rare case study highlights a multisystem autoimmune disease that emerged with symptoms of retinopathy and alopecia following COVID-19 vaccination. This finding contributes to the understanding of potential post-vaccination autoimmune responses.